{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T18:15:45Z","timestamp":1786385745256,"version":"build-2736575974"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,8]]},"DOI":"10.7759\/cureus.75314","type":"journal-article","created":{"date-parts":[[2024,12,8]],"date-time":"2024-12-08T11:38:21Z","timestamp":1733657901000},"source":"Crossref","is-referenced-by-count":2,"title":["Risk Factors Associated With the Development of Calciphylaxis in Patients With Chronic Kidney Disease: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Cyprian O","family":"Ogah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huda","family":"Mohammed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingie M","family":"Gabra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nouran","family":"Halawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saira","family":"Naeem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Safeera","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1080\/0886022X.2023.2256413","article-title":"Multimodality approach to treat calciphylaxis in end-stage kidney disease patients","volume":"45","author":"Lajoie C","year":"2023","unstructured":"Lajoie C, Ghanemi A, Bourbeau K, Sidib\u00e9 A, Wang YP, Desmeules S, Mac-Way F. Multimodality approach to treat calciphylaxis in end-stage kidney disease patients. Ren Fail. 2023, 45:2256413. 10.1080\/0886022X.2023.2256413","journal-title":"Ren Fail"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfz256","article-title":"The Australian Calciphylaxis Registry: reporting clinical features and outcomes of patients with calciphylaxis","volume":"36","author":"Ruderman I","year":"2021","unstructured":"Ruderman I, Toussaint ND, Hawley CM, Krishnasamy R, Pedagogos E, Lioufas N, Elder GJ. The Australian Calciphylaxis Registry: reporting clinical features and outcomes of patients with calciphylaxis. Nephrol Dial Transplant. 2021, 36:649-56. 10.1093\/ndt\/gfz256","journal-title":"Nephrol Dial Transplant"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.12659\/AJCR.930026","article-title":"The multifactorial pathogenesis of calciphylaxis: a case report","volume":"22","author":"Turek M","year":"2021","unstructured":"Turek M, St\u0119pniewska J, R\u00f3\u017ca\u0144ski J. The multifactorial pathogenesis of calciphylaxis: a case report. Am J Case Rep. 2021, 22:e930026. 10.12659\/AJCR.930026","journal-title":"Am J Case Rep"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-020-01722-y","article-title":"Calciphylaxis epidemiology, risk factors, treatment and survival among French chronic kidney disease patients: a case-control study","volume":"21","author":"Gaisne R","year":"2020","unstructured":"Gaisne R, P\u00e9r\u00e9 M, Menoyo V, Hourmant M, Larmet-Burgeot D. Calciphylaxis epidemiology, risk factors, treatment and survival among French chronic kidney disease patients: a case-control study. BMC Nephrol. 2020, 21:63. 10.1186\/s12882-020-01722-y","journal-title":"BMC Nephrol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2024.01.026","article-title":"Calciphylaxis episodes in the Australia and New Zealand Dialysis and Transplant Registry","volume":"9","author":"Toussaint ND","year":"2024","unstructured":"Toussaint ND, Davies CE, Bongetti E, et al.. Calciphylaxis episodes in the Australia and New Zealand Dialysis and Transplant Registry. Kidney Int Rep. 2024, 9:951-9. 10.1016\/j.ekir.2024.01.026","journal-title":"Kidney Int Rep"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocpiqo.2022.12.006","article-title":"Patient-reported and clinical outcomes among patients with calciphylaxis","volume":"7","author":"Wen W","year":"2023","unstructured":"Wen W, Krinsky S, Kroshinsky D, et al.. Patient-reported and clinical outcomes among patients with calciphylaxis. Mayo Clin Proc Innov Qual Outcomes. 2023, 7:81-92. 10.1016\/j.mayocpiqo.2022.12.006","journal-title":"Mayo Clin Proc Innov Qual Outcomes"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1080\/0886022X.2021.1884094","article-title":"Risk factors for calciphylaxis in Chinese hemodialysis patients: a matched case-control study","volume":"43","author":"Liu Y","year":"2021","unstructured":"Liu Y, Zhang X, Xie X, Yang X, Liu H, Tang R, Liu B. Risk factors for calciphylaxis in Chinese hemodialysis patients: a matched case-control study. Ren Fail. 2021, 43:406-16. 10.1080\/0886022X.2021.1884094","journal-title":"Ren Fail"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.902171","article-title":"Prevalence and clinical characteristics of calciphylaxis in Chinese hemodialysis patients","volume":"9","author":"Liu Y","year":"2022","unstructured":"Liu Y, Yang C, Yang X, et al.. Prevalence and clinical characteristics of calciphylaxis in Chinese hemodialysis patients. Front Med (Lausanne). 2022, 9:902171. 10.3389\/fmed.2022.902171","journal-title":"Front Med (Lausanne)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2018.10.002","article-title":"Treatment of calciphylaxis in CKD: a systematic review and meta-analysis","volume":"4","author":"Udomkarnjananun S","year":"2018","unstructured":"Udomkarnjananun S, Kongnatthasate K, Praditpornsilpa K, Eiam-Ong S, Jaber BL, Susantitaphong P. Treatment of calciphylaxis in CKD: a systematic review and meta-analysis. Kidney Int Rep. 2018, 4:231-44. 10.1016\/j.ekir.2018.10.002","journal-title":"Kidney Int Rep"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2020.08.014","article-title":"Calciphylaxis: risk factors and histologic findings in a case series from a tertiary care referral hospital [Article in Spanish]","author":"S\u00e1nchez-Pujol MJ","year":"2021","unstructured":"S\u00e1nchez-Pujol MJ, Docampo Sim\u00f3n A, Ill\u00e1n Gamb\u00edn F, Niveiro de Jaime M, Blanes Mart\u00ednez M. Calciphylaxis: risk factors and histologic findings in a case series from a tertiary care referral hospital [Article in Spanish]. Actas Dermosifiliogr (Engl Ed). 2021, S0001-7310(21)00164-2. 10.1016\/j.ad.2020.08.014","journal-title":"Actas Dermosifiliogr (Engl Ed)"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s40620-023-01707-8","article-title":"Cutaneous vascular calcifications in patients with chronic kidney disease and calcific uremic arteriolopathy: a cross-sectional study","volume":"36","author":"R\u00f8ndbjerg AK","year":"2023","unstructured":"R\u00f8ndbjerg AK, Gyldenl\u00f8ve M, Krustrup D, et al.. Cutaneous vascular calcifications in patients with chronic kidney disease and calcific uremic arteriolopathy: a cross-sectional study. J Nephrol. 2023, 36:1991-9. 10.1007\/s40620-023-01707-8","journal-title":"J Nephrol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.2147\/IJNRD.S241422","article-title":"Calciphylaxis: an analysis of concomitant factors, treatment effectiveness and prognosis in 30 patients","volume":"13","author":"Panchal S","year":"2020","unstructured":"Panchal S, Holtermann K, Trivedi N, Regunath H, Yerram P. Calciphylaxis: an analysis of concomitant factors, treatment effectiveness and prognosis in 30 patients. Int J Nephrol Renovasc Dis. 2020, 13:65-71. 10.2147\/IJNRD.S241422","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s40620-020-00908-9","article-title":"Calciphylaxis in end-stage kidney disease: outcome data from the United Kingdom Calciphylaxis Study","volume":"34","author":"Chinnadurai R","year":"2021","unstructured":"Chinnadurai R, Huckle A, Hegarty J, Kalra PA, Sinha S. Calciphylaxis in end-stage kidney disease: outcome data from the United Kingdom Calciphylaxis Study. J Nephrol. 2021, 34:1537-45. 10.1007\/s40620-020-00908-9","journal-title":"J Nephrol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1080\/0886022X.2023.2297566","article-title":"Clinical characteristics and treatment modalities in uremic and non uremic calciphylaxis - a dermatological single-center experience","volume":"46","author":"Yousuf S","year":"2024","unstructured":"Yousuf S, Busch D, Renner R, Schliep S, Erfurt-Berge C. Clinical characteristics and treatment modalities in uremic and non uremic calciphylaxis - a dermatological single-center experience. Ren Fail. 2024, 46:2297566. 10.1080\/0886022X.2023.2297566","journal-title":"Ren Fail"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-019-1301-6","article-title":"Phenprocoumon based anticoagulation is an underestimated factor in the pathogenesis of calciphylaxis","volume":"20","author":"Russ P","year":"2019","unstructured":"Russ P, Russwurm M, Kortus-Goetze B, Hoyer J, Kamalanabhaiah S. Phenprocoumon based anticoagulation is an underestimated factor in the pathogenesis of calciphylaxis. BMC Nephrol. 2019, 20:114. 10.1186\/s12882-019-1301-6","journal-title":"BMC Nephrol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/6661042","article-title":"Calcific uremic arteriolopathy: a case series and review from an inner-city tertiary university center in end-stage renal disease patients on renal replacement therapy","volume":"2021","author":"Omer M","year":"2021","unstructured":"Omer M, Bhat ZY, Fonte N, Imran N, Sondheimer J, Osman-Malik Y. Calcific uremic arteriolopathy: a case series and review from an inner-city tertiary university center in end-stage renal disease patients on renal replacement therapy. Int J Nephrol. 2021, 2021:6661042. 10.1155\/2021\/6661042","journal-title":"Int J Nephrol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijsu.2021.105906","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"88","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Int J Surg. 2021, 88:105906. 10.1016\/j.ijsu.2021.105906","journal-title":"Int J Surg"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijsu.2014.07.014","article-title":"Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration","volume":"147","author":"Vandenbroucke JP","year":"2007","unstructured":"Vandenbroucke JP, von Elm E, Altman DG, et al.. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Ann Intern Med. 2007, 147:163-94. 10.1016\/j.ijsu.2014.07.014","journal-title":"Ann Intern Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1097\/XEB.0000000000000155","article-title":"The updated Joanna Briggs Institute Model of Evidence-Based Healthcare","volume":"17","author":"Jordan Z","year":"2019","unstructured":"Jordan Z, Lockwood C, Munn Z, Aromataris E. The updated Joanna Briggs Institute Model of Evidence-Based Healthcare. Int J Evid Based Healthc. 2019, 17:58-71. 10.1097\/XEB.0000000000000155","journal-title":"Int J Evid Based Healthc"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j4008","article-title":"AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both","volume":"358","author":"Shea BJ","year":"2017","unstructured":"Shea BJ, Reeves BC, Wells G, et al.. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017, 358:j4008. 10.1136\/bmj.j4008","journal-title":"BMJ"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/304552-risk-factors-associated-with-the-development-of-calciphylaxis-in-patients-with-chronic-kidney-disease-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,8]],"date-time":"2024-12-08T11:38:22Z","timestamp":1733657902000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/304552-risk-factors-associated-with-the-development-of-calciphylaxis-in-patients-with-chronic-kidney-disease-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,8]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.75314","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12,8]]}}}